Sifuna Peter, Shaw Andrea V, Lucas Tina, Ogutu Bernards, Otieno Walter, Larsen David A
Kenya Medical Research Institute (KEMRI), Kisumu 40100, Kenya.
US Army Medical Research Directorate-Africa (USAMRD-A), Kisumu 00200, Kenya.
Vaccines (Basel). 2023 Jul 29;11(8):1299. doi: 10.3390/vaccines11081299.
Rotavirus is an important cause of fatal pediatric diarrhea worldwide. Many national immunization programs began adding rotavirus vaccine following a 2009 World Health Organization recommendation. Kenya added rotavirus vaccine to their immunization program at the end of 2014. From a cohort of 38,463 children in the Kisumu health and demographic surveillance site in western Kenya, we assessed how the implementation of the rotavirus vaccine affected mortality in children under 3 years of age. Following its introduction in late 2014, the span of rotavirus vaccine coverage for children increased to 75% by 2017. Receiving the rotavirus vaccine was associated with a 44% reduction in all-cause child mortality (95% confidence interval = 28-68%, < 0.0001), but not diarrhea-specific mortality ( = 0.401). All-cause child mortality declined 2% per month following the implementation of the rotavirus vaccine ( = 0.002) among both vaccinated and unvaccinated children, but diarrhea-specific mortality was not associated with the implementation of the rotavirus vaccine independent of individual vaccine status ( = 0.125). The incidence of acute diarrhea decreased over the study period, and the introduction of the rotavirus vaccine was not associated with population-wide trends ( = 0.452). The receipt of the rotavirus vaccine was associated with a 34% reduction in the incidence of diarrhea (95% confidence interval = 24-43% reduction). These results suggest that rotavirus vaccine may have had an impact on all-cause child mortality. The analyses of diarrhea-specific mortality were limited by relatively few deaths (n = 57), as others have found a strong reduction in diarrhea-specific mortality. Selection bias may have played a part in these results-children receiving rotavirus vaccine were more likely to be fully immunized than children not receiving the rotavirus vaccine.
轮状病毒是全球范围内导致儿童致命性腹泻的重要病因。2009年世界卫生组织发布建议后,许多国家的免疫规划开始添加轮状病毒疫苗。肯尼亚于2014年底在其免疫规划中添加了轮状病毒疫苗。我们从肯尼亚西部基苏木卫生与人口监测点的38463名儿童队列中,评估了轮状病毒疫苗的实施对3岁以下儿童死亡率的影响。2014年末引入该疫苗后,到2017年,儿童轮状病毒疫苗覆盖率增至75%。接种轮状病毒疫苗与全因儿童死亡率降低44%相关(95%置信区间 = 28 - 68%,P < 0.0001),但与腹泻特异性死亡率无关(P = 0.401)。在接种和未接种疫苗的儿童中,轮状病毒疫苗实施后,全因儿童死亡率每月下降2%(P = 0.002),但腹泻特异性死亡率与轮状病毒疫苗的实施无关,与个体疫苗接种状态无关(P = 0.125)。在研究期间,急性腹泻的发病率有所下降,轮状病毒疫苗的引入与全人群趋势无关(P = 0.452)。接种轮状病毒疫苗与腹泻发病率降低34%相关(95%置信区间 = 降低24 - 43%)。这些结果表明,轮状病毒疫苗可能对全因儿童死亡率产生了影响。腹泻特异性死亡率的分析因死亡人数相对较少(n = 57)而受到限制,其他人发现腹泻特异性死亡率有大幅降低。选择偏倚可能在这些结果中起了作用——接种轮状病毒疫苗的儿童比未接种的儿童更有可能获得全程免疫。